Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options

If you suffered losses in and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On May 7, 2025, Lantheus reported first-quarter results below market expectations, with Pylarify’s performance particularly falling short.

Then, on August 6, 2025, Lantheus again announced disappointing results. The company significantly reduced growth expectations for Pylarify—which had fallen 8.3% year-over-year—and slashed its fiscal year 2025 growth projections. Defendants attributed the losses to ongoing competition impacting Pylarify’s pricing dynamics.

In response to the August 6^th news, the price of Lantheus’ common stock declined 28.8% in a single day. The stock fell from a closing market price of $72.83 per share on August 5, 2025, to close at $51.87 per share on August 6, 2025.

To learn more about the Lantheus Holdings, Inc. investigation, go to www.faruqilaw.com/LNTH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106323773/en/